Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase I Study of Precision CRT for Liver-Dominant Metastatic Pancreatic Cancer With Homologous Recombination Deficiency (PreCISeRT)

Summary

The purpose of this phase I trial is to evaluate the safety and efficacy of the combination of conformal radiation therapy (RT) and Gemcitabine and Cisplatin in patients with metastatic pancreatic cancer that has spread to the liver.

General Information

NCT#: NCT05182112
Study ID: 21-443
Trial Phase: Phase I

Trial Sponsor: Memorial Sloan Kettering
Therapies Used in This Trial: Gemcitabine, Cisplatin

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search